Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2012

01-12-2012 | Research Article

The role of CCND1 alterations during the progression of cutaneous malignant melanoma

Authors: Laura Vízkeleti, Szilvia Ecsedi, Zsuzsa Rákosy, Adrienn Orosz, Viktória Lázár, Gabriella Emri, Viktória Koroknai, Tímea Kiss, Róza Ádány, Margit Balázs

Published in: Tumor Biology | Issue 6/2012

Login to get access

Abstract

It is well demonstrated that CCND1 amplification is a frequent event in the acral subtype of cutaneous malignant melanoma; however, its role in the other subtypes of the disease is still controversial. The objectives of this study were to evaluate genetic and expression alterations of CCND1 with a focus on primary cutaneous melanomas, to define BRAF and NRAS mutation status, and correlate the data with clinical–pathological parameters. CCND1 amplification was associated with ulceration and the localization of the metastasis. After correction for the mutation state of BRAF and NRAS genes, CCND1 amplification in samples without such mutations was associated with ulceration and sun exposure. The cyclin D1 (CCND1) mRNA level decreased in lesions with multiple metastases and was correlated with both the mRNA levels and mutation state of BRAF and NRAS genes. Primary melanomas with BRAF V600 or NRAS Q61 mutations exhibited lower CCND1 mRNA level. CCND1 protein expression was associated with Breslow thickness, metastasis formation, and shorter survival time. These observations suggest that CCND1 alterations are linked to melanoma progression and are modified by BRAF and NRAS mutations. Our data show that CCND1 amplification could have a prognostic relevance in cutaneous melanoma and highlight that altered CCND1 gene expression may influence the metastatic progression, survival, and the localization of metastases.
Appendix
Available only for authorised users
Literature
1.
Fu M, Wang C, Li Z, et al. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology. 2004;145:5439–47.PubMedCrossRef
2.
Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol. 2009;220:292–6.PubMedCrossRef
3.
Klein EA, Assoian RK. Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci. 2008;121:3853–7.PubMedCrossRef
4.
Lamb J, Ramaswamy S, Ford HL, et al. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell. 2003;114:323–34.PubMedCrossRef
5.
Tashiro E, Tsuchiya A, Imoto M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci. 2007;98:629–35.PubMedCrossRef
6.
Sauter ER, Yeo UC, von Stemm A, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res. 2002;62:3200–6.PubMed
7.
Walker JL, Assoian RK. Integrin-dependent signal transduction regulating cyclin D1 expression and G1 phase cell cycle progression. Cancer Metastasis Rev. 2005;24:383–93.PubMedCrossRef
8.
Zhong Z, Yeow WS, Zou C, et al. Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells. Cancer Res. 2010;70:2105–14.PubMedCrossRef
9.
Bartkova J, Lukas J, Muller H, et al. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res. 1995;55:949–56.PubMed
10.
Bastian BC, LeBoit PE, Hamm H, et al. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 1998;58:2170–5.PubMed
11.
Bringuier PP, Tamimi Y, Schuuring E, et al. Expression of cyclin D1 and EMS1 in bladder tumours; relationship with chromosome 11q13 amplification. Oncogene. 1996;12:1747–53.PubMed
12.
Elsheikh S, Green AR, Aleskandarany MA, et al. CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat. 2008;109:325–35.PubMedCrossRef
13.
Jin M, Inoue S, Umemura T, et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer. 2001;34:207–18.PubMedCrossRef
14.
Lazar V, Ecsedi S, Szollosi AG, et al. Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma. Mod Pathol. 2009;22:1367–78.PubMedCrossRef
15.
Sutherland RL, Musgrove EA. Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res. 2002;4:14–7.PubMedCrossRef
16.
Yang SX, Hewitt SM, Steinberg SM, et al. Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. Oncol Rep. 2007;17:281–7.PubMed
17.
Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135–47.PubMedCrossRef
18.
Gerami P, Jewell SS, Pouryazdanparast P, et al. Copy number gains in 11q13 and 8q24 [corrected] are highly linked to prognosis in cutaneous malignant melanoma. J Mol Diagn. 2011;13(3):352–8.PubMedCrossRef
19.
Bastian BC, Kashani-Sabet M, Hamm H, et al. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res. 2000;60:1968–73.PubMed
20.
North JP, Kageshita T, Pinkel D, et al. Distribution and significance of occult intraepidermal tumor cells surrounding primary melanoma. J Investig Dermatol. 2008;128:2024–30.PubMedCrossRef
21.
Smalley KS, Lioni M, Dalla Palma M, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther. 2008;7:2876–83.PubMedCrossRef
22.
Yamaura M, Takata M, Miyazaki A, et al. Specific dermoscopy patterns and amplifications of the cyclin D1 gene to define histopathologically unrecognizable early lesions of acral melanoma in situ. Arch Dermatol. 2005;141:1413–8.PubMedCrossRef
23.
de Andrade BA, León JE, Carlos R et al. (2012) Immunohistochemical expression of p16, p21, p27 and cyclin D1 in oral nevi and melanoma. Head Neck Pathol. 2012;6:297–304.
24.
Oba J, Nakahara T, Abe T, et al. Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma: an immunohistochemical study and analysis of prognostic value. J Dermatol Sci. 2011;62(2):116–23.PubMedCrossRef
25.
Gast A, Scherer D, Chen B, et al. Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study. Genes Chromosomes Cancer. 2010;49:733–45.PubMedCrossRef
26.
Gammon B, Ali L, Guitart J et al. (2012) Homogeneous staining regions for cyclin D1, a marker of poor prognosis in malignant melanoma. Am J Dermatopathol 34(5):487–490
27.
Alekseenko A, Wojas-Pelc A, Lis GJ, et al. Cyclin D1 and D3 expression in melanocytic skin lesions. Arch Dermatol Res. 2010;302:545–50.PubMedCrossRef
28.
Lazar V, Ecsedi S, Vízkeleti L, et al. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization. Melanoma Res. 2012;22(3):202–14.PubMedCrossRef
29.
Juhasz A, Balazs M, Sziklay I, et al. Chromosomal imbalances in laryngeal and hypopharyngeal cancers detected by comparative genomic hybridization. Cytometry A. 2005;67:151–60.PubMed
30.
Rakosy Z, Vizkeleti L, Ecsedi S, et al. EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis. Int J Cancer. 2007;121:1729–37.PubMedCrossRef
31.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25(4):402–8.PubMedCrossRef
32.
Koh SS, Opel ML, Wei JP, et al. Molecular classification of melanomas and nevi using gene expression microarray signatures and formalin-fixed and paraffin-embedded tissue. Mod Pathol. 2009;22:538–46.PubMedCrossRef
33.
Vizkeleti L, Ecsedi S, Rakosy Z, et al. Prognostic relevance of the expressions of CAV1 and TES genes on 7q31 in melanoma. Front Biosci (Elite Ed). 2012;4:1802–12.
34.
Lueking A, Beator J, Patz E, et al. Determination and validation of off-target activities of anti-CD44 variant 6 antibodies using protein biochips and tissue microarrays. Biotechniques. 2008;45:Pi-v.PubMedCrossRef
35.
Detre S, Saclani Jotti G, Dowsett M. A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995;48:876–8.PubMedCrossRef
36.
Gerami P, Jewell SS, Morrison LE, et al. Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol. 2009;33(8):1146–56.PubMedCrossRef
37.
Scolyer RA, Murali R, McCarthy SW, et al. Histologically ambiguous (“borderline”) primary cutaneous melanocytic tumors: approaches to patient management including the roles of molecular testing and sentinel lymph node biopsy. Arch Pathol Lab Med. 2010;134(12):1770–7.PubMed
38.
Abasolo A, Vargas MT, Ríos-Martín JJ et al. (2012) Application of fluorescence in situ hybridization as a diagnostic tool in melanocytic lesions, using paraffin wax-embedded tissues and imprint-cytology specimens. Clin Exp Dermatol. doi:10.​1111/​j.​1365-2230.​2012.​04416.​x
39.
Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206.PubMedCrossRef
40.
Nathanson KL. Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma. Biochem Pharmacol. 2010;80(5):755–61.PubMedCrossRef
41.
Nai G, Marques M. Role of ROC1 protein in the control of cyclin D1 protein expression in skin melanomas. Pathol Res Pract. 2011;207(3):174–81.PubMedCrossRef
42.
Xu C, Liu S, Fu H, et al. MicroRNA-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells. Eur J Cancer. 2010;46(15):2828–36.PubMedCrossRef
43.
Chen J, Feilotter HE, Pare GC, et al. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol. 2010;176(5):2520–9.PubMedCrossRef
44.
Metadata
Title
The role of CCND1 alterations during the progression of cutaneous malignant melanoma
Authors
Laura Vízkeleti
Szilvia Ecsedi
Zsuzsa Rákosy
Adrienn Orosz
Viktória Lázár
Gabriella Emri
Viktória Koroknai
Tímea Kiss
Róza Ádány
Margit Balázs
Publication date
01-12-2012
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2012
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0480-6

Other articles of this Issue 6/2012

Tumor Biology 6/2012 Go to the issue

Research Article

CYP1A1 Ile462Val polymorphism and cervical cancer: evidence from a meta-analysis

Research Article

Progesterone receptor (PR) variants exist in breast cancer cells characterised as PR negative

Research Article

Helicobacter pylori, a carcinogen, induces the expression of melanoma antigen-encoding gene (Mage)-A3, a cancer/testis antigen

Research Article

CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis

Research Article

CD74: a potential novel target for triple-negative breast cancer

Research Article

MMP1-1607 1G/2G polymorphism and lung cancer risk: a meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits